The project on the preventive and protective effects of neuraxial injection of ropivacaine on renal injury in preeclampsia women

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042447

Enrollment

Unknown

Registered

2021-01-21

Start date

2021-01-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

on the preventive and protective effects of intraspinal injection of ropivacaine on renal injury in preeclampsia women

Interventions

Labor analgesia group:Parturients undergo intraspinal delivery analgesia when the uterine orifice is 2cm dilated, and inject epidural test drugs

control group:no analgesia

Eligibility

Sex/Gender

Female

Age

25 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1) All women participating in the study signed an informed consent form. The age is between 25 and 35 years old; 2) Single pregnancy and primipara; 3) Gestational week > 37 weeks and fetal head position; 4) Pre-eclampsia: a) Mild preeclampsia: after 20 weeks of pregnancy, blood pressure >= 140/90mmHg; proteinuria: >= 300 mg/24h, protein/creatinine >= 0.3,random urine protein is more than 1+; it may be accompanied by upper abdominal discomfort, headache and other symptoms. b) Severe preeclampsia: Blood pressure >= 160/110mmHg; Proteinuria: >= 2000 mg/24h, serum creatinine >= 106µmol/L, random urine protein quantitative 2+; ALT or AST >= 1 times the normal value, jaundice; platelets < 100 x 10^9/L; microblood tube disease hemolysis LDH is elevated; persistent headache or other brain or visual disorders; persistent upper abdominal pain; 5) Those who have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) Originally suffering from medical and surgical complications: diabetes, chronic hypertension, heart/coronary artery disease, kidney disease, liver disease, anemia and other blood diseases, tumors, inflammation or immune diseases; 2) History of blood transfusion or blood therapy; 3) Obstetric complications such as abruption of placenta and placenta previa; 4) History of recurrent miscarriage; 5) Have a long-term history of opioid use; 6) Pregnant women with a history of headache or other neurological diseases or contraindications for intraspinal delivery analgesia; 7) Those who have difficulty in spinal canal puncture.

Design outcomes

Primary

Measure	Time frame
blood urea nitrogen;Serum creatinin;	—

Secondary

Measure	Time frame
24 h urine protein;Placental tissue marker molecule;	—

Countries

China

Contacts

Public ContactShen Sun

Department of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University

sunshen1980@126.com+86 15800391773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026